Article
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Investigational new drugs - 1 Oct 2010
Gollamudi Radharani, Ghalib Mohammad H, Desai Kavita K, Chaudhary Imran, Wong Benny, Einstein Mark, Coffey Matthew, Gill George M, Mettinger Karl, Mariadason John M, Mani Sridhar, Goel Sanjay
Abstract excerpt
BACKGROUND: Reolysin is reovirus serotype 3-Dearing strain, a double-stranded replication-competent RNA non-enveloped icosahedral virus. It induces cytopathic and anti-cancer effects in cells with an activated ras pathway due to inhibition of the dsRNA-activated protein kinase. METHODS: This was a single center dose escalation trial of Reolysin administered intravenously every 4 weeks in doses ranging from 1 x...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.